Fiche centre
Chicago Headache Center & Research Institute
Chicago — United States
Essais liés5clinical trials
VilleChicagolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06047457
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Rimegepant (PF-07899801) | Migraine | Phase 3 | NCT04743141 | Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine | RECRUITING |
| Elismetrep | Migraine | Phase 3 | NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
| Elismetrep | Migraine | Phase 3 | NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
| Rimegepant/BHV3000 | Migraine | Phase 3 | NCT04649242 | Randomized Study in Children and Adolescents With Migraine: Acute Treatment | RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047457 | E-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | ACTIVE_NOT_RECRUITING |